electroCore, Inc. (ECOR)

NASDAQ: ECOR · Real-Time Price · USD
6.81
-0.35 (-4.89%)
Mar 27, 2025, 4:00 PM EDT - Market closed
-4.89%
Market Cap 48.98M
Revenue (ttm) 25.18M
Net Income (ttm) -11.89M
Shares Out 7.19M
EPS (ttm) -1.59
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 158,470
Open 7.15
Previous Close 7.16
Day's Range 6.67 - 7.15
52-Week Range 5.32 - 19.49
Beta 0.25
Analysts Strong Buy
Price Target 25.50 (+274.45%)
Earnings Date Mar 12, 2025

About ECOR

electroCore, Inc., a commercial stage bioelectronic medicine and wellness company, provides non-invasive vagus nerve stimulation technology platform in the United States, the United Kingdom, and internationally. The company is developing gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga for the support of general healt... [Read more]

Industry Medical Devices
Sector Healthcare
IPO Date Jun 22, 2018
Employees 73
Stock Exchange NASDAQ
Ticker Symbol ECOR
Full Company Profile

Financial Performance

In 2024, electroCore's revenue was $25.18 million, an increase of 57.09% compared to the previous year's $16.03 million. Losses were -$11.89 million, -36.89% less than in 2023.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for ECOR stock is "Strong Buy." The 12-month stock price forecast is $25.5, which is an increase of 274.45% from the latest price.

Price Target
$25.5
(274.45% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

electroCore, Inc. (ECOR) Q4 2024 Earnings Call Transcript

electroCore, Inc. (NASDAQ:ECOR) Q4 2024 Results Conference Call March 12, 2025 5:30 PM ET Company Participants Dan Goldberger - CEO & Director Joshua Lev - Chief Financial Officer Conference Call Par...

14 days ago - Seeking Alpha

electroCore Announces Full Year 2024 Financial Results

Record f ull year 2024 net sales of $ 25.2 million increased 57% over $16.0 million for the full year 2023 driven by 85% annual growth of Rx gammaCore TM   in the United States Department of Veteran A...

15 days ago - GlobeNewsWire

electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2024 Financial Results on Wednesday, March 12, 2025

ROCKAWAY, N.J., March 06, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report its financial r...

21 days ago - GlobeNewsWire

electroCore to Participate at Upcoming Investor Conferences

Management to Attend the 37th Annual Roth Conference and the LSI USA '25 Management to Attend the 37th Annual Roth Conference and the LSI USA '25

22 days ago - GlobeNewsWire

electroCore, Inc. Announces Agreement with Spark Biomedical Inc. to Distribute Sparrow Ascent for Opioid Withdrawal

ROCKAWAY, N.J., Feb. 27, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Sparrow Ascent™ by Spark Biomed...

4 weeks ago - GlobeNewsWire

electroCore to Participate at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

ROCKAWAY, N.J., Feb. 04, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today its participation in the 12th Annual...

7 weeks ago - GlobeNewsWire

electroCore: An Opportunity In Medical And Wellness Device Innovation

electroCore, Inc. (ECOR) shows promising growth with a 45% YoY revenue increase and a 38% loss reduction, despite missing revenue expectations. The company's gammaCore device is FDA-cleared for headac...

2 months ago - Seeking Alpha

electroCore Has Only Just Begun To Scratch The Surface Of Its Huge TAM

electroCore's gammaCore, an FDA-approved nVNS device, generates recurring revenue and has significant expansion potential within the VA system and other healthcare channels. The company is diversifyin...

3 months ago - Seeking Alpha

electroCore to Acquire NeuroMetrix, Gaining Access to its Quell Platform and Positioning Itself as a Significant Player in Non-Invasive Bioelectronic Medicine and Wellness

The Quell® platform will strengthen our position as a significant player in the bioelectronic health and wellness sector

3 months ago - GlobeNewsWire

electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 21

ROCKAWAY, N.J., Nov. 14, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in ...

4 months ago - GlobeNewsWire

electroCore, Inc. (ECOR) Q3 2024 Earnings Call Transcript

electroCore, Inc. (NASDAQ:ECOR) Q3 2024 Earnings Call Transcript November 13, 2024 4:30 PM ET Company Participants Dan Goldberger - CEO & Director Joshua Lev - Chief Financial Officer Conference Call...

4 months ago - Seeking Alpha

electroCore Announces Third Quarter 2024 Financial Results

Record quarterly revenues driven by 75% YoY growth of Rx gammaCore™ in the VA/DoD and 147% increase in Truvaga™ sales

4 months ago - GlobeNewsWire

ElectroCore's Truvaga™ Plus Wins Men's Health Magazine Tech Award

ROCKAWAY, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, is proud to announce that its flagship wellness prod...

4 months ago - GlobeNewsWire

electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)

ROCKAWAY, N.J., Nov. 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Thomas Freebur...

4 months ago - GlobeNewsWire

electroCore to Participate at LD Micro Main Event VXII

Rockaway, New Jersey--(Newsfile Corp. - October 14, 2024) - electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will parti...

5 months ago - Newsfile Corp

Study Suggests Non-invasive Vagus Nerve Stimulation (nVNS) is effective in accelerating United States Air Force Pilot Training

Clinical trial demonstrates the ability of nVNS to accelerate sensorimotor learning in USAF Simulator Based Pilot Training Clinical trial demonstrates the ability of nVNS to accelerate sensorimotor le...

7 months ago - GlobeNewsWire

electroCore to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

ROCKAWAY, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will be participating in th...

7 months ago - GlobeNewsWire

electroCore, Inc. (ECOR) Q2 2024 Earnings Call Transcript

electroCore, Inc. (NASDAQ:ECOR) Q2 2024 Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Dan Goldberger - CEO Brian Posner - CFO Conference Call Participants Jeffrey Cohen - La...

8 months ago - Seeking Alpha

electroCore to Participate in Upcoming Investor Conferences

ROCKAWAY, N.J., Aug. 08, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the Company's CEO, Dan Goldberg...

8 months ago - GlobeNewsWire

electroCore Announces Second Quarter 2024 Financial Results

Seventh consecutive record quarterly net sales of $6.1 million, an increase of 73% over second quarter 2023  Company to host a conference call and webcast today, August 7, 2024 at 4:30 PM EST ROCKAWAY...

8 months ago - GlobeNewsWire

electroCore Announces the Commercial Launch of TAC-STIM™

ROCKAWAY, N.J., June 25, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, is thrilled to announce the Commercial Off the Shelf...

9 months ago - GlobeNewsWire

electroCore, Inc. Announces $9.3 Million Registered Direct Offering and Concurrent Private Placements Priced At Market Under Nasdaq Rules

ROCKAWAY, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced tha...

10 months ago - GlobeNewsWire

electroCore, Inc. (ECOR) Q1 2024 Earnings Call Transcript

electroCore, Inc. (NASDAQ:ECOR) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Dan Goldberger - CEO Brian Posner - CFO Conference Call Participants Jeffrey Cohen - Laden...

11 months ago - Seeking Alpha

electroCore Announces First Quarter 2024 Financial Results

Record first quarter 2024 net sales of $5.4 million, an increase of 96% over first quarter 2023 Company to host a conference call and webcast today, May 8, 2024 at 4:30 PM EST

11 months ago - GlobeNewsWire

electroCore to Announce First Quarter March 31, 2024 Financial Results on Wednesday, May 8, 2024

ROCKAWAY, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results...

11 months ago - GlobeNewsWire